TRNL2: A Gene Linked To Diabetes, Kidney Disease and Neurodegenerative Diseases

Target Name: TRNL2

NCBI ID: G4568

TRNL2

TRNL2: A Gene Linked To Diabetes, Kidney Disease and Neurodegenerative Diseases

TRNL2 (Tryptophan-Regulated Diuretic 2) is a gene encoded on the human chromosome. The protein it encodes is an important diuretic. Variations in the TRNL2 gene are associated with a variety of diseases, including kidney disease and neurodegenerative diseases. At the same time, TRNL2 has also been found to be a drug target, and its antagonists have been developed to treat a variety of neurological diseases. This article will introduce in detail the function of the TRNL2 gene, the relationship between mutations and diseases, and its discovery and application as a drug target.

1. Function of TRNL2 gene

The protein encoded by the TRNL2 gene is an important diuretic, which can inhibit the reabsorption of sodium ions by the kidneys, thereby increasing urine output, reducing blood volume, and producing a diuretic effect. Variations in the TRNL2 gene are associated with a variety of diseases, including kidney disease and neurodegenerative diseases. Kidney disease is a common disease that can cause damage to kidney function and cause symptoms such as edema, high blood pressure, and renal insufficiency. Neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, can cause nerve cell death and affect the normal function of the nervous system.

2. Variation of TRNL2 gene

Variations in the TRNL2 gene are associated with a variety of diseases. Studies have found that variations in the TRNL2 gene are associated with kidney disease and neurodegenerative diseases. For example, one study found that variations in the TRNL2 gene are associated with kidney diseases such as glomerulonephritis and diabetic nephropathy. In addition, a study found that variations in the TRNL2 gene are related to neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, etc.

3. Discovery of TRNL2 as a drug target

Antagonists of the TRNL2 gene have been developed to treat a variety of neurological diseases. For example, one study found that a TRNL2 antagonist could improve neuronal function by attenuating the effects of neuronal death in a model of Parkinson's disease. In addition, a study found that TRNL2 antagonists can improve learning and memory abilities in patients with Alzheimer's disease.

Protein Name: Mitochondrially Encoded TRNA Leucine 2 (CUN)

The "TRNL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRNL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets